Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Prevalence of heart failure (HF) with left ventricular (LV) diastolic dysfunction and
preserved ejection fraction (EF) (HFpEF) is increasing. Prognosis worsens with development of
pulmonary vasoconstriction and hypertension (PH) and right ventricular (RV) failure. The
investigators aimed at modulating pulmonary vascular tone and RV burden in HFpEF due to high
blood pressure (HBP), by using the phosphodiesterase-5 (PDE5) inhibitor sildenafil.